Evidence map›Paper›PMID 35042470›Full record

ArticleBMC nephrology2022

Xanthine oxidoreductase activity in platelet-poor and rich plasma as a oxidative stress indicator in patients required renal replacement therapy.

Elżbieta Cecerska-Heryć, Rafał Heryć, Grażyna Dutkiewicz, Anna Michalczyk, Bartłomiej Grygorcewicz, Natalia Serwin, Sylwia Napiontek-Balińska, Barbara Dołęgowska

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Elżbieta Cecerska-HeryćDepartment of Laboratory Medicine, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111, Szczecin, Poland. cecerskaela@wp.pl.ORCID 0000-0002-7313-7193
Rafał HeryćDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in Szczecin, Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
Grażyna DutkiewiczDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in Szczecin, Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
Anna MichalczykDepartment of Psychiatry, Pomeranian Medical University in Szczecin, Broniewskiego 26, 71-460, Szczecin, Poland.
Bartłomiej GrygorcewiczDepartment of Laboratory Medicine, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111, Szczecin, Poland.
Natalia SerwinDepartment of Laboratory Medicine, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111, Szczecin, Poland.
Sylwia Napiontek-BalińskaDepartment of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University in Szczecin, Powstancow Wielkopolskich 72, 70-111, Szczecin, Poland.
Barbara DołęgowskaDepartment of Laboratory Medicine, Pomeranian Medical University in Szczecin, Powstanców Wielkopolskich 72, 70-111, Szczecin, Poland.
Pomeranian Medical University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundXanthine oxidoreductase (XOR) is a hydroxylase enzyme involved in the metabolism of purines. XOR activity can vary: the homodimer protein can be converted into two different isoforms XD (antioxidant) and XO (prooxidant). Oxidative stress and inflammation that accompanying chronic kidney disease (CKD), dialysis, and kidney transplantation, resulted in platelet activation. Present study aimed to determine the influence of applied renal replacement therapy on xanthine oxidoreductase and its isoforms activity. MATERIALS AND

methodsThe study group consisted of 117 patients, divided into 4 groups: hemodialysis - 30 patients, peritoneal dialysis - 30 patients, kidney transplant patients - 27 and conservative treatment - 30 patients. The control group consisted of 30 healthy volunteers.

resultsSignificant differences were found in XOR activity in platelet-poor plasma (PPP) within the groups studied (p = 0.001). There was a relationship between the type of renal replacement therapy of all oxidoreductase isoforms in PPP (p < 0.001 all isoforms) and XD (p = 0.008), XO (p < 0.001) in platelet rich-plasma (PRP). A relationship was observed between the activity of all oxidoreductase isoforms in PPP and PRP, and the type of renal replacement therapy and the duration of dialysis and the age of patients. The cause of chronic kidney disease was also reflected differences in XD and XO activity in PPP.

conclusionsThe type of renal replacement therapy used in CKD patients, age of patients, duration of dialysis, CKD causes, and stage of progression significantly affect the activity of XOR and its isoforms.

Indexed as

Oxidative StressRenal Replacement TherapyAdultAgedBlood PlateletsFemaleHumansMaleMiddle AgedPlasmaRenal Insufficiency, ChronicXanthine DehydrogenaseXanthine DehydrogenaseAntioxidant enzymesChronic kidney diseasePlateletsRenal replacement therapyXanthine oxidoreductase

Identifiers

PMID35042470
PMCPMC8764817
OpenAlexW4220926438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.